Jazz Pharmaceuticals (JAZZ) Projected to Post Quarterly Earnings on Tuesday

Jazz Pharmaceuticals (NASDAQ:JAZZ) will likely be posting its quarterly earnings results after the market closes on Tuesday, February 25th. Analysts expect Jazz Pharmaceuticals to post earnings of $5.83 per share and revenue of $1.06 billion for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock opened at $136.01 on Monday. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The company has a market capitalization of $8.22 billion, a PE ratio of 19.16, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56. The firm’s 50-day moving average is $124.85 and its two-hundred day moving average is $118.07. Jazz Pharmaceuticals has a 12 month low of $99.06 and a 12 month high of $138.27.

Insiders Place Their Bets

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $122.31, for a total transaction of $183,465.00. Following the sale, the chief executive officer now owns 439,744 shares of the company’s stock, valued at approximately $53,785,088.64. This represents a 0.34 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 5,053 shares of company stock worth $617,442 in the last ninety days. 4.20% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have recently commented on JAZZ shares. TD Cowen reduced their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $130.00 to $170.00 in a research report on Thursday, February 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $207.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Royal Bank of Canada reissued an “outperform” rating and set a $179.00 price objective on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. One equities research analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $180.33.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.